Enrofloxacin Dosage, with a chemical name: 1-cyclopropyl-7- (4-ethyl-1-piperazinil) -6-fluoro-1,4-dihydro-4-oxo-3-quinoline carboxylic acid, a third-generation synthetic quinolone also known as ethylcyprofloxacin. It was first synthesized and tested in 1980. It was introduced into use for veterinary purposes in 1988. Enrofloxacin is an antibiotic of fluoroquinolone group, which has a wide spectrum of action against Gram-positive and Gram-negative bacteria and several types of Mycoplasma bacteria. Enrofloxacin hydrochloride is an effective antibiotic with MIC90 (minimum inhibitory concentration) of 0.312 mkg/ml for Mycoplasma bovis. Enrofloxacin is not active for anaerobic microorganisms.
It is not recommended for growing animals, as well as patients with cartilage tissue problems. It is not used in humans. The development of bacterial resistance is currently a topical problem in the use of enrofloxacin, for example bacteria such as Pseudomonas aeruginosa are now resistant to antibiotic action. The resistance of bacteria is due to a mutation of the bacterial cell in the direction of the formation of protective properties against antibiotic action.
One of the most important actions of enrofloxacin hydrochloride is the effective elimination of bacteria of the genus Leptospira in the body. Leptospirosis is considered to be the most widely spread bacterial zoonosis in the world, and it affects most mammals and humans. Tests to test the activity of enrofloxacin hydrochloride against the bacteria of the genus Leptospira were carried out on hamsters infected by Leptospira interrogans serovar Canicola. However, enrofloxacin is not the first antibiotic of choice against leptospirosis, mainly because it shows relatively high (1 – 4 µg/ml) MIC values and because other antibacterials are easier to reach therapeutic concentrations. However, studies have already tested a new recrystallised form of enrofloxacin hydrochloride dihydrate (enro-C). This molecule exhibits higher water solubility than the original compound and, as already shown, it has high bioavailability.
Application: It has well expressed activity against Gram-negative sticks and coccuses, including most species and strains of Pseudomonas aeruginosa, Klebsiella spp., E. coli, Enterobacter, Campylobacter, Shigella, Salmonella, Aeromonas, Haemophilus, Proteus, Yersinia, Serratia, and Vibrio species. At present, commercial forms of enrofloxacin and ciprofloxacin have even lower values than the early forms of the drug “minimal inhibitory concentration”. Other organisms that are sensitive to antibiotics include Brucella spp., Chlamydia trachomatis, Staphylococci, Mycoplasma, and Mycobacterium spp. and some others. Enrofloxacin, with a chemical name: 1-cyclopropyl-7- (4-ethyl-1-piperazinil) -6-fluoro-1,4-dihydro-4-oxo-3-quinoline carboxylic
It is generally not recommended for the treatment of streptococcal infections, as its activity in relation to them is variable. https://pillintrip.com/medicine/baytril-10 .Of great concern is the emergence of bacterial isolates resistant to enrofloxacin – Pseudomonas aeruginosa, Klebsiella pneumonia, Acinetobacter, and Enterococci.
is used to treat small pets (usually cats and dogs) and in agriculture to treat cattle, pigs, birds and other animals.
The most common veterinary drug containing the active ingredient of enrofloxacin is Baytril, produced by Bayer. This drug is actively used in the practice of veterinarians and shows effective work against a wide range of pathogenic bacteria causing various infectious diseases. It works at diseases of respiratory, digestive tract, at treatment of urinogenital infection, salmonellosis, septicemia, at treatment of secondary microflora during the course of virus diseases, and also many other things.
Produced enrofloxacin synthetically. The production process includes the following stages: ethylization, hydrolysis and neutralization. Production of the antibacterial drug enrofloxacin includes the following starting materials in proportion by weight: 1-1.5 ciprofloxacin, 0.3-1 ethylating agent, 4-6 ethanol with 95% concentration, 20-22 distilled water, 1-1.3 potassium hydroxide and 1-1.5 sulfuric acid. During the production process of the antibacterial preparation enrofloxacin it is not necessary to add a catalyst to avoid environmental pollution and harm to workers. The method of obtaining enrofloxacin is characterized by the fact that the synthesis process is carried out in a solvent, 1-cyclopropyl 6-fluoro-7-chloro-4-oxo-1,4-dihydroquinoline-3-carboxylate II is formed with the substitution of N- ethyl piperazine at a certain temperature. The desired product is then obtained by subsequent treatment with enrofloxacin.